Pharmacopeia

CWP-0249

Tapentadol

Neurology & Sedation · Level 2

Core pharmacology

Class Group

Centrally acting synthetic opioid with noradrenaline reuptake inhibition.

Main Action

Analgesia through combined mu-opioid receptor agonism and noradrenaline reuptake inhibition.

Mechanism of action

Mu-opioid receptor activation dampens nociceptive neurotransmission; inhibition of central noradrenaline reuptake augments descending inhibitory pain pathways. Analgesia is mediated by parent drug rather than an active opioid metabolite.

Indications Uses

Moderate to severe pain requiring opioid analgesia when alternatives are inadequate; immediate- and sustained-release products have different approved indications and dosing rules.

Absorption

Immediate-release oral tablet: peak concentration around 1.25 hours; mean absolute bioavailability approximately 32% due to first-pass metabolism.

Metabolism

Predominantly phase-II glucuronidation; CYP-mediated oxidation makes a smaller contribution. Metabolites are not known to contribute materially to analgesia.

Excretion

Parent drug and metabolites excreted almost entirely renally, predominantly as metabolites.

Half-life

Immediate-release terminal elimination half-life approximately 4 hours.

Adverse Effects Toxicity

Sedation, nausea, vomiting, constipation, respiratory depression, opioid dependence/misuse and overdose; marked risk with benzodiazepines and other CNS depressants.

Special Points

Do not regard tapentadol as a non-opioid or free of respiratory-depressant effects. Consider interactions with monoamine-oxidase inhibitors and other centrally acting medicines; observe opioid prescribing safeguards. IR and SR tablets are not interchangeable without regimen review.

Source references

These October 2026 additions were reconciled against the linked sources. Refer to current local formulary guidance for clinical prescribing.